340B drug discount savings help STD clinics and grantees expand access to quality and affordable sexual health care, the National Coalition of STD Directors (NCSD) says. | Shutterstock

Historic U.S. Rise in STDs Boosts 340B’s Importance, STD Program Directors Say

News this week that sexually transmitted disease (STD) reported cases in the U.S. reached all-time highs for the sixth straight year shows why STD clinic access to 340B drug discounts is vital, state and local STD program directors say.

New data published April 13 by U.S. Centers for Disease Control and Prevention found more than 2.5 million combined cases of chlamydia, gonorrhea, and syphilis reported in the U.S. in 2019, a nearly 30% increase in these STDs from 2015. “Preliminary 2020 data suggest that many of these concerning trends continued in 2020, when much of the country experienced major disruptions to STD testing and treatment services due to the COVID-19 pandemic,” CDC said in a news release.

News this week that sexually transmitted disease (STD) reported cases in the U.S. reached all-time highs for the sixth straight year shows why STD clinic access to 340B drug discounts is vital, state and local STD program directors say.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report